Press Release

CHAPEL HILL, N.C.--(BUSINESS WIRE)--July 16, 2007--POZEN Inc.
(NASDAQ: POZN), announced today that it will release second quarter
2007 results on July 26, 2007, before the market opens.

The announcement will be followed by a live webcast at 11:00 a.m.
Eastern Time with a discussion by POZEN management of the earnings and
business results. The webcast can be accessed on POZEN's website at
www.pozen.com and will be archived and available for replay. The
second quarter 2007 earnings release will be accessible in the News
section of POZEN's website.

POZEN is a pharmaceutical company committed to developing
therapeutic advancements for diseases with unmet medical needs where
it can improve efficacy, safety, and/or patient convenience. POZEN's
efforts are focused primarily on the development of pharmaceutical
products for the treatment of acute and chronic pain and other
pain-related conditions. POZEN has development and commercialization
alliances with GlaxoSmithKline for the proposed product candidate
Trexima(TM) combining sumatriptan, formulated with RT Technology(TM),
and naproxen sodium in a single tablet for the acute treatment of
migraine, which is currently under review by the United States Food
and Drug Administration, and with AstraZeneca for proprietary fixed
dose combinations of naproxen with the proton pump inhibitor
esomeprazole magnesium in a single tablet for conditions such as
osteoarthritis and rheumatoid arthritis in patients who are at risk
for developing NSAID-associated gastric ulcers. The company's common
stock is traded on The Nasdaq Stock Market under the symbol "POZN".
For detailed company information, including copies of this and other
press releases, see POZEN's website: www.pozen.com.